| |
ADAP Tipranavir Coverage in Discussions
|
| |
| |
Boehringer Ingelheim issued this Press Announcement on Friday July 15.
APTIVUS ACCESS TO BE BROADENED THROUGH AIDS DRUG ASSISTANCE PROGRAMS (ADAP)
Boehringer Ingelheim Pharmaceuticals, Inc. today announced an agreement was reached between the company and the ADAP Crisis Task Force, convened by the National Alliance of State and Territorial AIDS Directors, regarding Aptivus(r) (tipranavir), the anti-HIV drug recently approved by the FDA. Based on this agreement, Boehringer Ingelheim will work closely with state ADAPs to facilitate the inclusion of APTIVUS on ADAP formularies.
Viramune(r) (nevirapine) will continue to be available for patients who obtain their anti-HIV medications through ADAPs.
"This agreement reaffirms the commitment of Boehringer Ingelheim to assure that people who need our HIV medications will receive them," said Jim Rowenhorst of Boehringer Ingelheim Pharmaceuticals, Inc.
"ADAPs across the country are struggling to provide life-saving medications with funding that does not keep pace with the growing demand for services. Boehringer Ingelheim's participation in this agreement will help in our efforts to stabilize the program nationally," said Dwayne Haught, a member of NASTAD's ADAP Crisis Task Force.
This agreement marks an important step in broadened access for patients to APTIVUS and extended access to VIRAMUNE.
|
|
| |
| |
|
|
|
